Home Cart 0 Sign in  

[ CAS No. 850649-61-5 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 850649-61-5
Chemical Structure| 850649-61-5
Structure of 850649-61-5 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 850649-61-5 ]

Related Doc. of [ 850649-61-5 ]

Alternatived Products of [ 850649-61-5 ]

Product Details of [ 850649-61-5 ]

CAS No. :850649-61-5 MDL No. :MFCD09833196
Formula : C18H21N5O2 Boiling Point : -
Linear Structure Formula :- InChI Key :ZSBOMTDTBDDKMP-OAHLLOKOSA-N
M.W : 339.39 Pubchem ID :11450633
Synonyms :
SYR-322 free base;SYR 322
Chemical Name :(R)-2-((6-(3-Aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)benzonitrile

Calculated chemistry of [ 850649-61-5 ]

Physicochemical Properties

Num. heavy atoms : 25
Num. arom. heavy atoms : 12
Fraction Csp3 : 0.39
Num. rotatable bonds : 3
Num. H-bond acceptors : 4.0
Num. H-bond donors : 1.0
Molar Refractivity : 98.84
TPSA : 97.05 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : No
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -7.98 cm/s

Lipophilicity

Log Po/w (iLOGP) : 2.37
Log Po/w (XLOGP3) : 0.55
Log Po/w (WLOGP) : 0.01
Log Po/w (MLOGP) : 0.49
Log Po/w (SILICOS-IT) : 0.89
Consensus Log Po/w : 0.86

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 0.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -2.45
Solubility : 1.21 mg/ml ; 0.00357 mol/l
Class : Soluble
Log S (Ali) : -2.16
Solubility : 2.35 mg/ml ; 0.00692 mol/l
Class : Soluble
Log S (SILICOS-IT) : -3.31
Solubility : 0.165 mg/ml ; 0.000485 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 0.0
Synthetic accessibility : 3.51

Safety of [ 850649-61-5 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H302-H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 850649-61-5 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 850649-61-5 ]
  • Downstream synthetic route of [ 850649-61-5 ]

[ 850649-61-5 ] Synthesis Path-Upstream   1~13

  • 1
  • [ 1246610-74-1 ]
  • [ 850649-61-5 ]
YieldReaction ConditionsOperation in experiment
83% With trifluoroacetic acid In methanol at 65℃; for 7 h; 160.0 g, 0.36 mol of the precursor (III) of alogliptin and 2 L of methanol were added to the reaction flask,Stirring to dissolve, adding 46.0g trifluoroacetic acid, stirring the reaction at 65 ° C for 7 hours until the reaction is complete,The reaction solution was added dropwise to 2 L of water under stirring, stirred for 30 minutes, filtered,The filter cake and saturated sodium bicarbonate solution were mixed and stirred for 30 minutes, filtered, washed with water cake,Isopropanol - ethanol mixed solvent recrystallization, 60 ° C under vacuum for 12 hours,Obtained as a white solid 102.5g, yield 83percent, purity 98.9percent, melting point 126 ~ 128°C.
77.82% for 2 h; Reflux Potassium carbonate was removed by filtration under reduced pressure, and the filtrate was transferred to a reaction flask was slowly added citric acid (14.41g, 0.075mol), was stirred and heated to reflux, the reaction was refluxed for 2 hours, the reaction system has a large amount of solid precipitated.Filtration under reduced pressure, the filter cake was rinsed with tert-butanol 50ml.The resulting white solid was suction filtered (wet product) was added to 30ml of purified water, adjusted PH to 9.5 with a base, and extracted four times with dichloromethane (4 * 30ml), all organic phases were combined, washed with saturated sodium bicarbonate solution, the organic phase 3 times (3 * 30ml), then washed with saturated brine 3 times (3 * 30ml), the organic phase was dried over anhydrous sodium sulfate.Vacuum drying agent was removed by filtration, and the filtrate was concentrated under reduced pressure, dried to give a white solid 13.20g.Yield: 77.82percent, content: 99.10percent.
75.13% With trifluoroacetic acid In dichloromethane at 25℃; 250mL three-neck flask was added 200g of dichloromethane, 20.0g of Intermediate IV was added under stirring, was slowly dropwiseadded 56.0g of trifluoroacetic acid (feed solution was added dropwise a process control temperature below 25 deg.] C), after complete addition 25 ± 5 , the reaction was monitored by HPLC area normalization. When the content of intermediate IV was less than 1percent, the reaction was stopped. After cooling tobelow10, 20percent sodium hydroxide solution was slowly added (control Feed temperature 10 ~ 20 ) adjust the pH of the feed liquid to 11 ~12.After the pH adjustment, additional 30g of water was added and stirring was continued for 20 ± 5 min. The layers were separated and separated into layers. The organicphase wascollectedand the aqueous phase was extracted once with 48 g of dichloromethane. First washed with 80g water once, and then washed once with48g saturated sodium chloride solution, fully separated aqueous layer was added to the organic phase was dried 12h anhydrous sodium sulfate 2 ~ 3h,after the end of centrifugation filtration, the filter cake with a small amount of two Chlorine rinse once, the combined washing filtrate was concentrated under reduced pressure at 55 ~ 70 ° CDichloromethane, and then concentrated under reduced pressure 1h.After the concentration was completed, 45g of ethyl acetate was added while hot, heated to reflux to make the solid solution slowly cooled to 0± 5 , crystallization 60 ± 10min precipitated the solid full, filtered, the filter cake with a small amount of ethyl acetate washed once thrown sufficientlydry placed in a vacuum oven at 60 ± 5 dried to a weight loss of less than 1percent, to give 11.6 g of alogliptin fine, pale yellow solidsubstance, by HPLC area normalization purity of 99.9percent as measured , Yield 75.13percent.
74% With hydrogenchloride; ethanol In dichloromethane at -5 - 25℃; Example 3:Alogliptin free base To the 1250cc methylene dichloride charged0.57mole of formula- VII (where R=BOC) and stirred for 10-30 min at a temperature of -5 to 25°C. 400cc 20-25percent alcoholic hydrochloric acid was added for 30-90 min slowly and the reaction mass was stirred for 45-100 min at ambient temperature. After completion of reaction, the solvent was distilled out under vacuum. Charged lOOOcc water, washed aqueous layer with 2530cc methylenedichloride, collected organic layer and extracted with 960cc Water. Collected total aqueous layer and washed with 2530cc methylenedichloride and basify the aqueous layer with 10percent NaOH solution, extracted with 2530cc methylenedichloride, collected organic layer and distilled under reduced pressure at 30-50°C and further recrystallized the product in methyl tertiary butyl ether, and finally filtered the product and the wet product was dried at 30-60°C to afford 74percent of title compound. HPLC PURITY: 99-100percent
3.21 g With hydrogenchloride In dichloromethane; water at 10 - 25℃; for 1 h; 4.40 g of compound (2) was dissolved in 45 ml of dichloromethane at about 25 ° C,Stir,Cooling to about 10 ° C, dropwise adding 10 ml of concentrated hydrochloric acid,Reaction for 1 hour;Add water 20 ml, liquid separation,The organic layer was extracted twice with water, 15 ml each time and the aqueous layer was combined.Add 20percent aqueous sodium hydroxide solution to the water layer, adjust pH to pH = 10, stir for 2 hours,A large amount of solid precipitated, filtered, washed with water and the solid dried to give 3.21 g of alogliptin,

Reference: [1] Patent: CN104086527, 2016, B, . Location in patent: Paragraph 0052; 0061-0063; 0074
[2] Patent: CN105777709, 2016, A, . Location in patent: Paragraph 0069; 0070
[3] Patent: CN106336396, 2017, A, . Location in patent: Paragraph 0013-0119
[4] Patent: WO2015/92807, 2015, A1, . Location in patent: Sheet 8
[5] Patent: CN103910710, 2017, B, . Location in patent: Paragraph 0064-0065
  • 2
  • [ 865758-96-9 ]
  • [ 850649-61-5 ]
YieldReaction ConditionsOperation in experiment
85% With triethylamine In isopropyl alcohol at 65℃; for 17 h; (2) the step obtained in the same manner as in (1), 236 g of 2-(6-chloro-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl-methyl)benzonitrile, (R) -3-aminopiperidine dihydrochloride (223 g, 1.29 mol), Isopropanol1000mL And triethylamine (261 g, 2.58 mol) Followed by adding to the reactor,Stirred for 20 minutes,Stirring was continued and the temperature was raised to 65 ° C for 17 hours (the progress of the reaction was monitored by HPLC)After completion of the reaction,The reaction solution was concentrated to dryness at 60 ± 5 ° C under reduced pressure, 2500 mL of purified water was added and stirred for 20 minutes. The solid was not dissolved and left to stand for 1 hour, filtered and the wet cake was further mixed with 5000 mL of purified water for 10 minutes. Filter, the two filtrate combined with lmol / L sodium hydroxide solution ρ Ξ = 10 ± 0.5, dichloromethane extraction, separation of methylene chloride layer, layer of methylene chloride anhydrous magnesium sulfate drying, filtration, the filtrate 50 ± 5 Deg.] C to give 2- [[6- [(3R) -3-amino- 1 -piperidinyl] -3,4-dihydro-3-methyl-2,4-dioxo (2H) -pyrimidinyl] methyl] benzonitrile 2488, yield: 85percent, purity 98.2percent.
85.7% With tetra-n-butylphosphonium chloride; sodium hydrogencarbonate In water; toluene at 60 - 70℃; (2) 5.28 g of the intermediate obtained in step (1) was added to the reaction flask, followed by the successive addition of 27.63 g of toluene, 16.00 g of water, 0.03 g of tetrabutylphosphine chloride, 3.81 g (R-3-aminopiperidine dihydrochloride and 6.44 g of sodium bicarbonate were heated to 60-70 °C and the sample was controlled by HPLC until the disappearance of the intermediate was complete. After the completion of the reaction, the reaction system was cooled to 20 ~ 25 °C, filtered, the filter cake was added toluene 10mL, heated to 110 °C reflux, then slowly cooled to 0 ~ 5 °C heat 0.5 ~ 1h, filtered, The filter cake was dried under reduced pressure at a temperature of 50-60 °C to obtain 5.57 g of alogliptin with a purity of 99.95percent and a yield of 85.7percent.
80% With sodium hydrogencarbonate In isopropyl alcohol at 100℃; for 2 h; Molecular sieve General procedure: A mixture of 6c (8 g, 22.5 mmol), (R)-3-aminopiperidine dihydrochloride (4.67 g, 27 mmol), NaHCO3 (9.45 g, 112.5 mmol) and activated 4 Å MS (2.6 g) in isopropanol (150 mL) was stirred at 100 °C for 2 h. The reaction mixture was filtered through Celite and concentrated in vacuo. The residue was diluted with DCM, washed with water and saturated brine, dried over anhydrous Na2SO4, and concentrated. The crude product was purified by flash chromatography (DCM/MeOH/TEA, 100:0.5:0.5) to give pure 2h as a light yellow solid (8 g, 85percent).
72.79% With triethylamine In water; isopropyl alcohol at 60℃; for 13 h; 5.0 g of 2 - [(6-chloro-3,4-dihydro-3-methyl-2,4-dioxo-1 (2H) -pyrimidinyl) methyl]Benzonitrile (Compound III, R1 is H), 3.30 g of (R) -3-aminopiperidine dihydrochloride and 8.00 g of triethylamine were dissolved in a mixed solution of 60 ml of isopropanol and 1 ml of water, and the temperature was raised to 60 ° C The reaction was stirred for 13h. The reaction was cooled to room temperature and 60 ml of a mixed solution of acetonitrile and heptane was slowly added dropwise. After stirring for 1 hour, the mixture was stirred under ice-cooling for 1 hour and filtered with suction to obtain 5.23 g of crude compound V with a yield of 84.97percent and a purity of 95.80percent. The crude compound was recrystallized from isopropanol, filtered, washed and dried to give 4.48 g of pure compound V. The purification yield was 85.66percent. The total yield of compound V was 72.79percent and the purity was 99.50percent.
70% With sodium hydrogencarbonate In methanol at 100℃; for 2 h; Molecular sieve 2-(6-Chloro-3-methyl-2,4-dioxo-3,4-dihydro-2-H-pyrimidin-1-ylmethyl)-benzonitrile (330 mg, 1.08 mmol), (R)-3-amino-piperidine dihydrochloride (246 mg, 1.4 mmol) and sodium bicarbonate (500mg, 5.4 mmol) were stirred with 200 mg activated molecular sieves (4A) in dry MeOH (5 mL) at 100 °C for 2 h. The reaction was filtered through Celite, concentrated in vacuo, and then diluted with CHCl3, and washed with water. The water phase was extracted with CHCl3 and the combined organic phases were washed with water, dried (Na2SO4), and filtered. TFA (1mL) was added into the solution which was then concentrated in vacuo. The residue was dissolved in a small amount of MeOH, and Et2O was added to force precipitation. The mixture was allowed to stand at RT overnight. It will be understood by those skilled in the art that condensation with the amine or amine hydrochloride may be performed in a solvent or mixture of solvents with a base, such as potassium carbonate, sodium bicarbonate and the like, or mixtures thereof. The solvent may comprise both protic and aprotic solvents, or mixtures thereof. For example, the solvent may comprise a mixture of isopropyl alcohol and water. Further, the reaction may be heated to about 30-100 °C, preferably about 35-55 °C, and more preferably about 45-50 °C until the reaction is complete. Solvents were decanted, and the solid was washed with Et2O two times to give 270 mg product as off-white powder. It will also be understood that the product may be further purified by washing with an organic solvent or mixture of solvents. Non-limiting examples of solvent or solvent mixtures include isopropyl acetate, ethyl acetate, dichloromethane, heptane, and the like. Further, the product may optionally be purified by column chromatography. The benzonitrile product may be isolated as the free base if desired, but preferably, the product may be further converted to the corresponding acid addition salt, such as the benzoic acid salt. Preferably, the benzonitrile product is treated with benzoic acid to form 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl]-benzonitrile benzoate (4). Preparation and isolation of the benzoate salt may be performed by conventional methods for the formation of acid addition salts. 1H-NMR (400 MHz, CDCl3-CD3OD 10:1): δ 7.82 (d, 1H, J = 7.6 Hz), 7.65 (t, 1H, J = 7.6 Hz), 7.46 (t, 1H, J = 7.6 Hz), 7.23 (d, 1H, J = 8.0 Hz), 5.42 (s, 1H), 5.50-5.00 (ABq, 2H, J = 41.6, 15.2 Hz), 3.30 (m, 2H), 3.16 (s, 3H), 2.91 (m, 1H), 2.76 (m, 2H), 1.93 (m, 1H), 1.79 (m, 1H), 1.51 (m, 2H). MS (ES) [m+H] calc'd for C18H22N5O2, 340.2; found, 340.2.
42 g With sodium hydrogencarbonate In methanol at 65 - 70℃; for 6 h; Molecular sieve Step - III: Preparation of (R)-2-((6-(3-aminopiperidin-l-yl)-3-methyl-2,4-dioxo-3,4- dihydropyrimidin-l(2H)-yl)methyl)benzonitrile (Alogliptin)Methanol (518 ml), 2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydropyrimidin- l(2H)-yl)methyl)benzonitrile (41.5 gm), sodium bicarbonate (63 gm), (R)-piperidin-3- amine dihydrochloride salt (34 gm) and molecular sieves (25 gm) were added at room temperature under stirring. The temperature of the reaction mass was raised to 65 to 70°C and maintained for 6 hours. The reaction mass was filtered through hi-flow bed and the solvent was distilled off under vacuum at low temperature to obtain a residual solid. To the residual solid was added water (275 ml) and pH was adjusted to 7.0. The reaction mass was extracted with methylene chloride and then the layers were separated. The organic layer was dried with sodium sulfate and then concentrated to obtain a solid. The solid obtained was then dried to obtain 42 gm of alogliptin

Reference: [1] Patent: CN103980249, 2016, B, . Location in patent: Paragraph 0014; 0038; 0040
[2] Patent: CN107954978, 2018, A, . Location in patent: Paragraph 0044; 0055
[3] European Journal of Medicinal Chemistry, 2014, vol. 83, p. 547 - 560
[4] Patent: CN106608853, 2017, A, . Location in patent: Paragraph 0037; 0038; 0039; 0041
[5] Patent: EP1586571, 2005, A1, . Location in patent: Page/Page column 43-44
[6] Journal of Medicinal Chemistry, 2007, vol. 50, # 10, p. 2297 - 2300
[7] Patent: US2007/66635, 2007, A1, . Location in patent: Page/Page column 14; 14-15
[8] Patent: WO2010/72680, 2010, A1, . Location in patent: Page/Page column 15-16
[9] Patent: WO2013/46229, 2013, A1, . Location in patent: Page/Page column 20
[10] Patent: CN104193726, 2016, B, . Location in patent: Paragraph 0056-0057
  • 3
  • [ 4318-56-3 ]
  • [ 22115-41-9 ]
  • [ 850649-61-5 ]
YieldReaction ConditionsOperation in experiment
73%
Stage #1: With dmap In acetonitrile at 80℃; for 6 h; Green chemistry
Stage #2: for 8 h; Reflux; Green chemistry
A solution of 6-chloro-3-methyl uracil (20.0 g, 125 mmol), acetonitrile (200 mL), 2- cyanobenzyl bromide (27.0 g, 138 mmol), N, N- diisopropylethyl Amine (96.8 g, 750 mmol) and warmed to reflux (80 ° C) for 6 hours.(R) -3-Aminopiperidine dihydrochloride (23.6 g, 138 mmol) was added and reflux was continued for 8 hours.After the reaction was completed, the temperature was lowered to 30 ° C, added to 1000 mL of water, and then cooled to 5 ° C and stirred for 4 hours.Filter, filter cake washed twice with water, each 400 mL, pumpingdry. Get alogliptin 31.0 g. Yield 73percent, purity 99.8percent.
Reference: [1] Patent: CN106366068, 2017, A, . Location in patent: Paragraph 0016; 0017; 0018
  • 4
  • [ 309956-78-3 ]
  • [ 865758-96-9 ]
  • [ 850649-61-5 ]
Reference: [1] Organic Letters, 2018, vol. 20, # 2, p. 473 - 476
  • 5
  • [ 22115-41-9 ]
  • [ 850649-61-5 ]
Reference: [1] Journal of Medicinal Chemistry, 2007, vol. 50, # 10, p. 2297 - 2300
[2] Patent: WO2013/46229, 2013, A1,
[3] European Journal of Medicinal Chemistry, 2014, vol. 83, p. 547 - 560
[4] Patent: WO2015/92807, 2015, A1,
[5] Patent: CN103980249, 2016, B,
[6] Patent: US2016/340333, 2016, A1,
[7] Patent: CN103524483, 2016, B,
[8] Patent: CN104193726, 2016, B,
[9] Patent: CN106608853, 2017, A,
[10] Patent: CN106336396, 2017, A,
[11] Patent: CN107954978, 2018, A,
  • 6
  • [ 865758-95-8 ]
  • [ 850649-61-5 ]
Reference: [1] Journal of Medicinal Chemistry, 2007, vol. 50, # 10, p. 2297 - 2300
[2] Patent: WO2013/46229, 2013, A1,
[3] European Journal of Medicinal Chemistry, 2014, vol. 83, p. 547 - 560
[4] Patent: US2016/340333, 2016, A1,
  • 7
  • [ 4318-56-3 ]
  • [ 850649-61-5 ]
Reference: [1] Patent: WO2015/92807, 2015, A1,
[2] Patent: WO2015/92807, 2015, A1,
[3] Patent: CN103980249, 2016, B,
[4] Patent: CN103524483, 2016, B,
[5] Patent: CN104193726, 2016, B,
[6] Patent: CN106608853, 2017, A,
[7] Patent: CN106336396, 2017, A,
[8] Patent: CN107954978, 2018, A,
  • 8
  • [ 4318-56-3 ]
  • [ 22115-41-9 ]
  • [ 850649-61-5 ]
Reference: [1] Organic Letters, 2018, vol. 20, # 2, p. 473 - 476
  • 9
  • [ 612-13-5 ]
  • [ 850649-61-5 ]
Reference: [1] Patent: WO2015/92807, 2015, A1,
[2] Patent: CN106608853, 2017, A,
  • 10
  • [ 865758-96-9 ]
  • [ 850649-61-5 ]
Reference: [1] Patent: WO2015/92807, 2015, A1,
[2] Patent: CN103524483, 2016, B,
  • 11
  • [ 7032-11-3 ]
  • [ 850649-61-5 ]
Reference: [1] Patent: US2017/81305, 2017, A1,
[2] Patent: US2017/81305, 2017, A1,
  • 12
  • [ 127294-73-9 ]
  • [ 850649-61-5 ]
Reference: [1] Patent: CN103524483, 2016, B,
  • 13
  • [ 309956-78-3 ]
  • [ 850649-61-5 ]
Reference: [1] Patent: CN106336396, 2017, A,
Same Skeleton Products
Historical Records